On February 16, 2024, the Food and Drug Administration (FDA) announced the approval of osimertinib, marketed under the brand name Tagrisso by AstraZeneca Pharmaceuticals LP, in combination with platinum-based chemotherapy. This approval offers a new treatment avenue for adult patients battling locally advanced or metastatic non-small cell lung cancer (NSCLC) characterized by specific genetic mutations: EGFR exon 19 deletions or exon 21 L858R mutations. These mutations must be identified using an FDA-approved test, ensuring the targeted application of this therapy.

The Clinical Landscape of NSCLC (Non small cell lung cancer)

Non-small cell lung cancer represents a significant portion of lung cancer diagnoses, distinguished from small cell lung cancer by its pathology and progression. Within NSCLC, genetic mutations such as those affecting the epidermal growth factor receptor (EGFR) play a crucial role in the disease’s development and progression. osimertinib (TAGRISSO®), an EGFR tyrosine kinase inhibitor (TKI), specifically targets these mutations, providing a mechanism to combat the aggressive spread of cancer cells, including the potential to address challenging conditions like brain metastases and central nervous system involvement.

Osimertinib (TAGRISSO®) Path to Approval

The FDA’s decision was rooted in the results from the FLAURA 2 clinical trial (NCT04035486), a rigorous, open-label, randomized study involving 557 patients. This trial compared the efficacy of osimertinib (TAGRISSO®) in combination with platinum-based chemotherapy to osimertinib (TAGRISSO®) monotherapy in patients with no prior systemic therapy for their advanced disease. The combination therapy’s superiority was evident in its significant improvement in progression-free survival (PFS), showcasing a median PFS of 25.5 months compared to 16.7 months for the monotherapy group. These results underscore the potential of osimertinib (TAGRISSO®) to enhance patient outcomes by delaying disease progression.

Adverse Reactions and Administration Guidelines

The integration of osimertinib (TAGRISSO®) with chemotherapy introduces considerations for healthcare professionals, particularly regarding adverse effects. Common reactions include leukopenia, thrombocytopenia, and neutropenia, among others, necessitating careful patient monitoring. The recommended dose for osimertinib (TAGRISSO®) is 80 mg orally once daily, a regimen that continues until disease progression or the emergence of unacceptable toxicity.

The Role of Project Orbis in Approval

This approval underscores the global effort to expedite the delivery of promising cancer treatments through Project Orbis, an FDA initiative. By collaborating with international partners such as the Australian Therapeutic Goods Administration (TGA), Health Canada, and Switzerland’s Swissmedic, the FDA aims to streamline the review process, ensuring broader, more rapid access to new therapies.

The Importance of Mutation Testing in Lung Cancer

The specificity of osimertinib (TAGRISSO®)’s target highlights the importance of accurate mutation testing in NSCLC. By identifying patients with EGFR exon 19 deletions or exon 21 L858R mutations, healthcare providers can tailor treatments to the genetic profile of the tumor, embodying the principles of precision medicine.

Implications for Patient Care

The approval of osimertinib (TAGRISSO®) with chemotherapy for EGFR-mutated NSCLC marks a significant advancement in lung cancer treatment. It not only broadens the arsenal available to oncologists but also emphasizes the importance of genetic profiling in determining the most effective treatment strategies. As research continues, the role of targeted therapies like osimertinib (TAGRISSO®) in the adjuvant setting and for early-stage disease will likely expand, potentially transforming the standard of care for lung cancer patients.

Looking Forward

The journey of osimertinib (TAGRISSO®) from clinical trials to FDA approval is a testament to the dedication of the medical and scientific community in their quest to improve lung cancer treatment. As healthcare professionals incorporate osimertinib (TAGRISSO®) into clinical practice, ongoing observation and research will be vital in optimizing its use and understanding its full impact on patient outcomes, including overall survival rates and quality of life.

This approval also sets a precedent for future drug development and approval processes, highlighting the importance of international collaboration, expedited review programs, and the integration of precision medicine into cancer care. As osimertinib (TAGRISSO®) becomes a part of standard treatment regimens, its role in improving the lives of those affected by NSCLC will continue to be evaluated and refined, ensuring that patients receive the most effective and personalized care possible.

Reference: FDA approves osimertinib with chemotherapy for EGFR-mutated non-small cell lung cancer – https://bit.ly/3I4OkHW

Related OncologyTube Video: FLAURA2: Should this Positive Trial Change Practice for EGFRm+ NSCLC